By enGenes Biotech…
Subscribe to Supplier
Subscribe to Supplier
Presenting first prototype for continuous recombinant protein production at RPP 12 Germany
Vienna, Austria: – Bioprocessing solutions expert enGenes Biotech is ready to unveil the first working prototype of a fully automated and integrated platform for true continuous production of recombinant proteins and plasmid DNA.
The prototype will form the subject of a presentation by its Bioprocess Scientist Florian Simon, detailing the results of his PhD doctoral research resulting from enGenes’ engagement with the ECOnti program.
Smart and stable platform
Florian’s presentation “ECOnti – Advancing integrated continuous manufacturing with microbial cells” will show how the project has succeeded in building a working platform that proves it can provide at least 30 days of fully continuous, automated microbial bioproduction that is stable, smart, and seamlessly integrated.
This has been developed by enGenes, using its -eXcite high-yield E. coli continuous expression system. In collaboration with QUBICON’s real-time control platform, Novasign and SimVantage for process modelling and scale-up tools, Tosoh Bioscience adaptive, multicolumn chromatography for separation and purification, and Vienna’s University of Natural Resources and Life Sciences (BOKU) expertise in primary recovery, DSP & economic modeling. The whole project has received funding from Austria’s FFG Research Promotion Agency.
Efficiency and sustainability advantages
Florian Simon commented: “I hope to show how this is a significant breakthrough not just for speed and efficiency but also for sustainability, with fewer experiments, faster scale-up, up to 90% less consumption of water and energy, and predictive, end-to-end process control.”
About enGenes Biotech
With over a decade of proven expertise, enGenes Biotech develops bioprocesses which consistently outperform conventional approaches. Their proprietary technology platform delivers higher yields, faster timelines, and superior scalability for recombinant proteins, peptides and plasmid DNA production in E. coli – directly translating into reduced production costs and accelerated market entry. From early concept to industrial process, they enable pharmaceutical, diagnostic and industrial applications to achieve results that set new industry benchmarks at a fraction of the cost.
enGenes Biotech’s expertise spans every step of the biomanufacturing lifecycle: molecular biology, upstream and downstream processing, analytics, process scale-up, product development, and market entry. They deliver tailored solutions that reduce costs, advance sustainable innovation, and improve customers’ competitive position on the global marketplace.
The company offers development and manufacturing services for recombinant proteins, peptides, and plasmid DNA tailored to the needs of pharmaceutical and industrial biotech companies. Their integrated service portfolio ensures efficiency, quality, and speed in tackling even the toughest challenges. In addition, they are building a portfolio of high-quality and cost-effective products, with an initial focus on endonucleases and protein A-based affinity ligands.
Find out more at: https://www.engenes.cc
About RPP 2025
The Recombinant Protein Production (RPP) conference is a biennial event that offers a comprehensive overview of current challenges and innovative solutions in recombinant protein production, focusing on the comparative physiologies of microbial and higher eukaryotic platforms for protein production.
The 2025 RPP conference (RPP12) is a three-day event opening October 7 at the Edwin-Scharff-Haus cultural centre on the banks of the Danube in the southern German city of Ulm.
The conference will build on the successes of previous meetings, which have attracted steadily increasing numbers of researchers from both academia and the bioprocessing industry. The meeting will again address the application of recombinant proteins in areas such as biocatalysis, food and bio-pharmacy, this time focusing on topics such as chassis and bioprocess engineering, impacts of production conditions and the model-enabled optimisation and prediction of target proteins, hosts and processes.
The event is organized by the Microbial Biotechnology Division of the European Federation of Biotechnology (EFB), with further information at: http://www.efbiotechnology.org/RPP.
Resources
Click on What if microbial protein production didn’t have to stop? for further information and video of continuous microbial biomanufacturing in action.
Click on Contact enGenes to setup one-to-one meeting at RPP 12 in Ulm.
Click on ECOnti – Accelerated, Low Ecological Footprint, Manufacturing to download factsheet on project.
enGenes Bioprocess Scientist Florian Simon has been closely involved in the ECOnti program.
Dr. Juergen Mairhofer, CEO and co-founder, enGenes Biotech GmbH.
Related Articles
